CEO Robeson Reeves is optimistic about the market's robustness and the long-term potential for the company's Casinos & Resorts assets. Despite this, shares are down more than 25% year-to-date.
Q4 results fell short of estimates with disappointing revenue, operating margin, and EPS. The company's International Interactive segment underperformed. Analysts predict an increase in Bally's cash burn, implying a drop in its LTM free cash flow margin from negative 1.3% to negative 2.9%.
Gainers: •$Ballys (BALY.US)$+6% (announces modified "Dutch auction" tender offer to purchase shares at $19.25-$22) •$Ferguson (FERG.US)$+3.4% (enters entered into a non-discretionary arrangement with its brokers J.P. Morgan Securities in continuation of its $2 billion share repurchase program) •$Bausch Health (BHC.US)$+3.3% (chairman resigns) •$赛诺菲安万特 (SNY.US)$+3.2% (Sanofi-GSK first to report a successful efficacy study against ...
$Ballys (BALY.US)$The General has put in the bid of 38.00 per share for Ballys! There are 400,000 shorts that still have to cover. Surprised more people didn’t buy in on Guaranteed profit. Still not too late to make a small gain. I got in at 35.45. It could get interesting after 37.00. Hoping shorts cover in premarket. Who knows something crazy might happen, I mean it is Ballys.
Ballys股票讨论
• $Ballys (BALY.US)$ +6% (announces modified "Dutch auction" tender offer to purchase shares at $19.25-$22)
• $Ferguson (FERG.US)$ +3.4% (enters entered into a non-discretionary arrangement with its brokers J.P. Morgan Securities in continuation of its $2 billion share repurchase program)
• $Bausch Health (BHC.US)$ +3.3% (chairman resigns)
• $赛诺菲安万特 (SNY.US)$ +3.2% (Sanofi-GSK first to report a successful efficacy study against ...
暂无评论